X0508 4 2026-01-31 0001438533 Travere Therapeutics, Inc. TVTX 0001763494 Dube Eric M C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 true true false false CHIEF EXECUTIVE OFFICER 1 Common Stock 2026-01-31 4 A 0 113800 0 A 532973 D Common Stock 2026-02-03 4 S 0 66452 32.06 D 466521 D Common Stock 2026-02-03 4 S 0 33635 32.70 D 432886 D Employee stock option (right to buy) 33.095 2026-01-31 4 A 0 303600 0 A 2036-01-31 Common Stock 303600 303600 D Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. The weighted average sale price for the transaction reported was $32.06, and the range of prices were between $31.52 and $32.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $32.70, and the range of prices were between $32.5248 and $32.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-02-03